News
-
-
PRESS RELEASE
G.ST Antivirals reports start of Phase II trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer
G.ST Antivirals starts Phase II trial and appoints Ronald Bruce Turner as new Chief Medical Officer. Trial aims to assess effectiveness of novel antiviral nasal spray against respiratory viruses -
PRESS RELEASE
G.ST Antivirals reports positive Phase I trial results for 2-Deoxy-D-glucose against upper respiratory infections
G.ST Antivirals reports positive Phase I trial results for 2-Deoxy-D-glucose (2-DG) against upper respiratory infections and secures over EUR 6 million for Phase II clinical trial. The intranasal administration of 2-DG was found to be safe, well tolerated, and did not lead to any serious adverse events (SAEs). The compound targets rhinoviruses and coronaviruses, offering potential broad-spectrum antiviral treatment against respiratory tract infections. The successful financing round includes a EUR 4 million Series A funding led by xista science ventures (xsv), with additional commitment from the Life Sciences Programme of the Austrian Research Promotion Agency (FFG). G.ST Antivirals, a spin-off from the Medical University of Vienna, is on track to advance its innovative drug against colds and other viral infections, with the Phase II clinical trial set to commence in the first half of 2024.
-
LaMar’s Donuts Celebrates National Donut Day 2024
-
abrdn U.S. Closed-End Funds Announce Distribution Payment Details
-
abrdn Income Credit Strategies Fund Announces Update and Tentative Closing Date for Acquisition of Assets From First Trust High Income Long/Short Fund
-
Electric Royalties Announces Interest Conversion Under Convertible Credit Facility
-
Pfister Faucets' American Plumber Stories Docuseries Wins Three Telly Awards
-
EQS-Adhoc: Vectron Systems AG: Vectron enters into Business Combination Agreement, resolves 10% capital increase without subscription rights of the shareholders and supports voluntary public acqusition offer
-
CPI PROPERTY GROUP publishes financial results for the first quarter of 2024
-
Leclanché SA: Publishes its Annual Report 2023 and Non-financial ESG Report
-
Spexis receives second extension for the publication of its 2023 annual report until July 31, 2024, releasing its unaudited financial statements and providing an update on its dispute with SPRIM.
-
Molten Ventures Plc: HOL-Holding(s) in Company
-
ACCOR - Description of own share buyback programme
-
ACCOR - Press release following the 2024 general meeting
-
Capital increase through exercise of subscription rights
-
NFL BIOSCIENCES: RESULTS OF THE COMBINED GENERAL MEETING OF MAY 30, 2024
-
Thales has completed the sale of its Ground Transportation Systems business